The current therapeutic approach for anaemia after kidney transplant
4
Issued Date
2023-01-01
Resource Type
ISSN
10624821
eISSN
14736543
Scopus ID
2-s2.0-85142940918
Pubmed ID
36250458
Journal Title
Current Opinion in Nephrology and Hypertension
Volume
32
Issue
1
Start Page
35
End Page
40
Rights Holder(s)
SCOPUS
Bibliographic Citation
Current Opinion in Nephrology and Hypertension Vol.32 No.1 (2023) , 35-40
Suggested Citation
Nissaisorakarn V., Nissaisorakarn P., Kantachuvesiri S. The current therapeutic approach for anaemia after kidney transplant. Current Opinion in Nephrology and Hypertension Vol.32 No.1 (2023) , 35-40. 40. doi:10.1097/MNH.0000000000000842 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/82632
Title
The current therapeutic approach for anaemia after kidney transplant
Author's Affiliation
Other Contributor(s)
Abstract
Purpose of reviewAnaemia after kidney transplantation is a common finding with no uniform management guideline. Most approaches are derived from the chronic kidney disease (CKD) population. Recent advances for the treatment of anaemia in patients with CKD/End stage renal disease include hypoxia-inducible factor-prolyl hydroxylase inhibitor (HIF-PHi), a novel class of oral erythropoietin-stimulating agents (ESAs). We present relevant studies of HIF-PHi in the transplant population and its implications on the management of posttransplant anaemia.Recent findingsData on HIF-PHi use in the kidney transplant population are promising. Limited data demonstrate a significant increase in haemoglobin, with a comparable safety profile to epoetin. Reported adverse effects include overcorrection and low iron stores.SummaryCurrent therapeutic approaches to anaemia in the kidney transplant population is mostly derived from the CKD population. More studies are needed on HIF-Phi, a novel class of ESAs that has thus far demonstrated promise in the kidney transplant population.